Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors

Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors

<p dir="ltr">Tyrosine kinase inhibitors (TKIs) have remarkably transformed Ph+ chronic myeloid leukemia (CML) management; however, TKI resistance remains a major clinical challenge. Mutations in <i>BCR-ABL1</i> are well studied but fail to explain 20–40% of resistant case...

Full description

Saved in:
Bibliographic Details
Main Author: Mohamed A. Ismail (418629) (author)
Other Authors: Gheyath K. Nasrallah (9200525) (author), Maria Monne (4166524) (author), Ali AlSayab (17150992) (author), Mohamed A. Yassin (8361183) (author), Govindarajulu Varadharaj (14778931) (author), Salma Younes (6424865) (author), Claudio Sorio (212799) (author), Richard Cook (70389) (author), Helmout Modjtahedi (532099) (author), Nader I. Al-Dewik (14152884) (author)
Published: 2022
Subjects:
Biological sciences
Genetics
Biomedical and clinical sciences
Cardiovascular medicine and haematology
Clinical sciences
Chronic Myeloid Leukemia
Protein Tyrosine Phosphatase Receptor Type G
BCR-ABL1
Single Nucleotide Polymorphisms
Tyrosine Kinase Inhibitors
Therapeutic Modalities
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items